ESPR - NASDAQ

Esperion Therapeutics, Inc.

ESPR·NASDAQ

$3.14

+0.32%

HealthcareBiotechnology

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$652.83M

EPS-0.1100

P/E Ratio-28.55

Earnings Date08/04/2026

espr

Net Common Stock Issuance

Last Annual Value

98.35M

3-Year CAGR

5-Year CAGR

31%

10-Year CAGR

-6%

Adjust for Inflation

Esperion Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

ESPR · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Esperion Therapeutics, Inc. NASDAQ:ESPR	98.35M	20.0%	-14.8%	N/A
SIGA Technologies, Inc. NASDAQ:SIGA	0.00	N/A	N/A	N/A
Emergent BioSolutions Inc. NYSE:EBS	-22.70M	N/A	N/A	N/A
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS	36.43M	66.8%	-9.8%	-6.5%
Olema Pharmaceuticals, Inc. NASDAQ:OLMA	208.30M	17.1%	172.3%	N/A
REGENXBIO Inc. NASDAQ:RGNX	1.01M	-46.8%	-65.9%	N/A
Ventyx Biosciences, Inc. NASDAQ:VTYX	95.05M	25.2%	-9.8%	N/A
Absci Corporation NASDAQ:ABSI	109.14M	402.1%	-12.3%	N/A
Orthofix Medical Inc. NASDAQ:OFIX	5.93M	5.0%	-7.6%	N/A
Aquestive Therapeutics, Inc. NASDAQ:AQST	103.46M	126.4%	28.3%	N/A

Esperion Therapeutics, Inc. Fair Value Envelope

ESPR · NASDAQ

Our analysis suggests that ESPR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Esperion Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.14

Related Guides

Blog Categories

Continue your ESPR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.